MCID: CRV002
MIFTS: 46

Cervix Uteri Carcinoma in Situ

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 12 15
Carcinoma in Situ of Uterine Cervix 12 71
Cervical Intraepithelial Neoplasia 43 71
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 12
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 71
Squamous Intraepithelial Neoplasia, Grade Iii 12
Cin Iii - Carcinoma in Situ of Cervix 12
Severe Dysplasia of the Cervix Uteri 12
Cin Iii - Severe Dyskaryosis 12
Carcinoma in Situ of Cervix 12
Carcinoma of Cervix Stage 0 12
Severe Dysplasia of Cervix 12
Cervix Ca in Situ 12
Cin Iii 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8991
ICD9CM 34 233.1
MeSH 43 D018290
SNOMED-CT 67 92564006
ICD10 32 D06 D06.9
UMLS 71 C0206708 C0851140 C2987516

Summaries for Cervix Uteri Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the uterine cervix.

MalaCards based summary : Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to cervicitis and cervical intraepithelial neoplasia. An important gene associated with Cervix Uteri Carcinoma in Situ is MIR548B (MicroRNA 548b), and among its related pathways/superpathways are Glioblastoma Multiforme and Senescence and Autophagy in Cancer. The drugs Aluminum hydroxide and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include uterine cervix, cervix and testes.

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases in the Rare Cancer of Cervix Uteri family:

Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 cervicitis 31.4 SERPIND1 GP6 GP5 CDKN2A
2 cervical intraepithelial neoplasia 31.1 KRT17 FHIT CDKN2A
3 familial retinoblastoma 30.9 TP53 RB1 CDKN2A
4 chronic cervicitis 30.7 SERPIND1 KRT17 GP6 GP5 CDKN2A
5 in situ carcinoma 30.7 TP53 MIR654 MIR548B LCOR KRT17 CDKN2A
6 squamous cell papilloma 30.7 TP53 CDKN2A
7 vulvar intraepithelial neoplasia 30.6 TP53 CDKN2A
8 vaginal disease 30.5 TP53 LINC01191 GP5
9 cervical squamous cell carcinoma 30.4 TP53 KRT17 CDKN2A
10 epidermodysplasia verruciformis 1 30.3 TP53 GP6 GP5
11 keratinizing squamous cell carcinoma 30.3 TP53 LINC01191 CDKN2A
12 anus cancer 30.3 TP53 LINC01191 GP6 GP5 CDKN2A
13 endocervical adenocarcinoma 30.2 TP53 MAPK8IP1 CDKN2A
14 oropharynx cancer 30.2 TP53 GP6 GP5 CDKN2A
15 vaginal cancer 30.1 TP53 MAPK8IP1 LINC01191 INSM1 GP5 CDKN2A
16 vulva cancer 30.1 TP53 LINC01191 GP5 CDKN2A
17 suppressor of tumorigenicity 3 30.0 TP53 RB1 FHIT CDKN2A
18 cervical incompetence 29.9 PTPRN MAPK8IP1 INSM1
19 anogenital venereal wart 29.8 TP53 LINC01191 GP6 GP5 CDKN2A
20 cervical cancer 29.5 TP53 RUBCNL RB1 MIR338 KRT17 FHIT
21 cervix carcinoma 29.4 TP53 PTPRN MAPK8IP1 INSM1 GP5 FHIT
22 cervix disease 28.8 TP53 PTPRN MIR338 MAPK8IP1 LCOR INSM1
23 chlamydia 10.7
24 immune deficiency disease 10.6
25 bacterial vaginosis 10.6
26 vaginal discharge 10.6
27 early invasive cervical adenocarcinoma 10.5 INSM1 CDKN2A
28 cervical adenosarcoma 10.5 GP6 GP5
29 retinoblastoma 10.5
30 prostate squamous cell carcinoma 10.4 TP53 CDKN2A
31 endometrial squamous cell carcinoma 10.4 TP53 CDKN2A
32 ovarian seromucinous carcinoma 10.4 TP53 CDKN2A
33 esophagus verrucous carcinoma 10.4 TP53 CDKN2A
34 spitz nevus 10.4 TP53 CDKN2A
35 focal epithelial hyperplasia 10.4 GP6 GP5
36 bizarre leiomyoma 10.4 TP53 CDKN2A
37 vaginitis 10.4
38 herpes simplex 10.4
39 comedo carcinoma 10.4 TP53 LCOR GP5
40 localized osteosarcoma 10.3 TP53 CDKN2A
41 tumor of exocrine pancreas 10.3 TP53 CDKN2A
42 large cell acanthoma 10.3 TP53 KRT17
43 adenosquamous carcinoma 10.3
44 placenta disease 10.3
45 47,xyy 10.3
46 cytokine deficiency 10.3
47 cervical clear cell adenocarcinoma 10.3 MAPK8IP1 GP5
48 urinary bladder inverted papilloma 10.3 RB1 CDKN2A
49 cervical adenoid basal carcinoma 10.3 MAPK8IP1 KRT17
50 inverted follicular keratosis 10.3 KRT17 GP6 GP5

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):


Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:



Diseases related to Cervix Uteri Carcinoma in Situ

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
6 Antimetabolites Phase 4
7 Monophosphoryl lipid A Phase 4
8 Hypolipidemic Agents Phase 4
9 Anticholesteremic Agents Phase 4
10 Lipid Regulating Agents Phase 4
11 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
12 Anesthetics, Local Phase 4
13 Adrenergic beta-Agonists Phase 4
14 Adrenergic alpha-Agonists Phase 4
15 Respiratory System Agents Phase 4
16 Adrenergic Agents Phase 4
17 Epinephryl borate Phase 4
18 Vasoconstrictor Agents Phase 4
19 Anti-Asthmatic Agents Phase 4
20 Mydriatics Phase 4
21 Bronchodilator Agents Phase 4
22 Adrenergic Agonists Phase 4
23 Sympathomimetics Phase 4
24 Neurotransmitter Agents Phase 4
25
Aluminum sulfate Approved Phase 3 10043-01-3
26
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
27
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
28
Bevacizumab Approved, Investigational Phase 3 216974-75-3
29
Pancrelipase Approved, Investigational Phase 3 53608-75-6
30
Eugenol Approved Phase 3 97-53-0 3314
31
leucovorin Approved Phase 3 58-05-9 6006 143
32
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
33
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
34
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
35
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37
Fenretinide Investigational Phase 3 65646-68-6
38
3,3'-diindolylmethane Investigational Phase 3 1968-05-4
39 Immunologic Factors Phase 3
40 Retinamide Phase 3
41 Dermatologic Agents Phase 3
42 Immunoglobulins Phase 3
43 Antibodies Phase 3
44 Hemostatics Phase 3
45 Pharmaceutical Solutions Phase 3
46 Antiviral Agents Phase 3
47 Keratolytic Agents Phase 3
48 Sodium Channel Blockers Phase 3
49 Anti-Arrhythmia Agents Phase 3
50 Diuretics, Potassium Sparing Phase 3

Interventional clinical trials:

(show top 50) (show all 320)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
4 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
5 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
6 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
7 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Completed NCT03629886 Phase 4
8 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
9 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
10 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
11 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
12 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Active, not recruiting NCT03180034 Phase 4
13 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
14 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
15 The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Unknown status NCT03366493 Phase 3
16 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
17 A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00003075 Phase 3 Fenretinide
18 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
19 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
20 Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 Completed NCT00929526 Phase 3
21 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
22 Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) Completed NCT00212381 Phase 3 di indolylmethane (DIM)
23 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
24 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
25 An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1] Completed NCT00462813 Phase 3 oral microencapsulated diindolylmethane
26 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3 Fluorouracil
27 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
28 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
29 Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial Completed NCT01505920 Phase 3
30 Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
31 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
32 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
33 A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. Completed NCT00995020 Phase 3
34 Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Completed NCT02330471 Phase 3
35 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
36 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
37 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
38 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
39 Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens Completed NCT00973362 Phase 3
40 A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Completed NCT00001073 Phase 3 Isotretinoin
41 A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessors), Parallel Active Controlled Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (Produced by AryoGen Pharmed) Plus FOLFIRI-3 Compared With Bevacizumab (Avastin®) Plus FOLFIRI-3 in Patients With Metastatic Colorectal Cancer (mCRC) Completed NCT03288987 Phase 3 Bevacizumab + FOLFIRI-3
42 Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? Completed NCT01014026 Phase 3
43 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
44 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients. Completed NCT00677677 Phase 3
45 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
46 Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL Recruiting NCT03721978 Phase 3
47 A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, the Reference Drug, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients Recruiting NCT03391934 Phase 3 Cetuximab + FOLFIRI
48 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix Active, not recruiting NCT03185013 Phase 3
49 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
50 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Active, not recruiting NCT02733068 Phase 3

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Genetic Tests for Cervix Uteri Carcinoma in Situ

Anatomical Context for Cervix Uteri Carcinoma in Situ

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Uteri Carcinoma in Situ:

19
Uterine Cervix

MalaCards organs/tissues related to Cervix Uteri Carcinoma in Situ:

40
Cervix, Testes, T Cells, Endothelial, Breast, Lymph Node, Skin

Publications for Cervix Uteri Carcinoma in Situ

Articles related to Cervix Uteri Carcinoma in Situ:

(show top 50) (show all 7725)
# Title Authors PMID Year
1
Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. 61
31648368 2020
2
The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study. 61
31846057 2020
3
Differences Between Squamous Intraepithelial Lesions of the Vulva and the Cervix. 61
32501869 2020
4
P16/Ki-67 Immunostaining in the Triage of Postmenopausal Women With Low-Grade Cytology Results. 61
32574476 2020
5
Associations between the expression of SCCA, MTA1, P16, Ki-67 and the infection of high-risk HPV in cervical lesions. 61
32566016 2020
6
Correlation Between p16/Ki-67 Expression and the Grade of Cervical Intraepithelial Neoplasias. 61
32515923 2020
7
Risk of Recurrence After Treatment for Cervical Intraepithelial Neoplasia 3 and Adenocarcinoma In Situ of the Cervix: Recurrence of CIN 3 and AIS of Cervix. 61
32384365 2020
8
HLA-B*38:165N and HLA-B*51:309 alleles identified in two Chinese cervical intraepithelial neoplasia patients. 61
32026562 2020
9
Risk of High-Grade Histopathology Diagnosed by Cervical Conization in Endocervical Curettage Cervical Intraepithelial Neoplasia 1: A Case-Control Study. 61
32324695 2020
10
Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation. 61
32157438 2020
11
Factors associated with cervical intraepithelial neoplasia (CIN2/CIN3), early stage and advanced stage of cervical cancer diagnosis in the Brazilian Amazonian region. 61
31577564 2020
12
Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. 61
31718233 2020
13
Effects of Implementing the Dual Papanicolaou Test Interpretation of ASC-H and LSIL Following Bethesda 2014. 61
32556080 2020
14
Do High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net Hospital. 61
32569024 2020
15
LLETZ make it simple: Anxiety, pain and treatment outcomes with outpatient large loop excision of the transformation zone under local anaesthesia. 61
32002985 2020
16
Cervical neoplastic lesions in relation to CD4 T-lymphocyte counts and antiretroviral therapy among women with clinical stage 1 HIV in Yunnan, China. 61
31913555 2020
17
Changes in the incidence of cervical tumours by disease stage in a cytology-based screening programme. 61
31690178 2020
18
Intraoperative Human Papillomavirus Test Predicts 24-Month High-Grade Squamous Intraepithelial Lesion Recurrence Saving Costs: A Prospective Cohort Study. 61
32569022 2020
19
Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. 61
32517663 2020
20
Course of cervical intraepithelial neoplasia diagnosed during pregnancy. 61
32322982 2020
21
Avoiding Unnecessary Treatment of Cervical Intraepithelial Neoplasia Grade 2. 61
31344228 2020
22
Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia. 61
31344234 2020
23
Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis. 61
32276936 2020
24
Correction: Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis. 61
32487687 2020
25
Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: Concurrent cohorts with a 5-year follow-up. 61
31583683 2020
26
DNA methylation for cervical cancer screening: a training set in China. 61
32576279 2020
27
Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development. 61
32546712 2020
28
The challenges of colposcopy for cervical cancer screening in LMICs and solutions by artificial intelligence. 61
32493320 2020
29
The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden. 61
32552719 2020
30
Evaluation of p16/Ki-67 Dual-Stained Cytology in Triaging HPV-Positive Women during Cervical Cancer Screening. 61
32156721 2020
31
Compliance with follow-up Test of Cure and outcomes after treatment for high-grade cervical intraepithelial neoplasia in Victoria, Australia. 61
31950488 2020
32
Candidate HPV genotypes not included in the 9-valent vaccine for prevention of CIN 2-3. 61
32467333 2020
33
Impact of HPV vaccination on cervical screening performance: a population-based cohort study. 61
32362659 2020
34
HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory. 61
32475726 2020
35
Identification of HPV genotypes causing cervical precancer using tissue-based genotyping. 61
32037535 2020
36
Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study. 61
31868230 2020
37
The use of miRNA in the early detection of cervical intraepithelial neoplasia. 61
32417880 2020
38
Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis. 61
32363604 2020
39
Application of 5-aminolevulinic acid photodynamic therapy for vaginal intraepithelial neoplasia, a report of six cases. 61
32473400 2020
40
Fifteen new nucleotide substitutions in variants of human papillomavirus 18 in Korea : Korean HPV18 variants and clinical manifestation. 61
32448303 2020
41
Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework. 61
32245832 2020
42
Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA. 61
31490545 2020
43
Risk of Cervical Dysplasia After Colposcopy Care and Risk-Informed Return to Population-Based Screening: A Systematic Review. 61
31679914 2020
44
Interlaboratory concordance of p16/Ki-67 dual-staining interpretation in HPV-positive women in a screening population. 61
32168431 2020
45
Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. 61
32282601 2020
46
The Role of CADM1 and MAL Promoter Methylation in Inflammation and Cervical Intraepithelial Neoplasia. 61
32311274 2020
47
Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. 61
32390320 2020
48
Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study. 61
31880054 2020
49
Atypical glandular lesions of the cervix and risk of cervical cancer. 61
31853943 2020
50
Cervical Cancer Screening with Human Papillomavirus Self-Sampling Among Transgender Men in El Salvador. 61
32407149 2020

Variations for Cervix Uteri Carcinoma in Situ

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Pathways for Cervix Uteri Carcinoma in Situ

Pathways related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.63 TP53 RB1 CDKN2A
2 11.57 TP53 RB1 CDKN2A
3 11.46 TP53 RB1 FHIT
4 11.2 TP53 RB1 CDKN2A
5 10.84 TP53 RB1 CDKN2A
6 10.37 GP6 GP5
7 10.14 TP53 RB1 CDKN2A

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 9.16 TP53 CDKN2A
2 Ras protein signal transduction GO:0007265 9.13 TP53 RB1 CDKN2A
3 hemostasis GO:0007599 8.8 SERPIND1 GP6 GP5

Molecular functions related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.8 TP53 RB1 CDKN2A

Sources for Cervix Uteri Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....